Targeting thromboinflammation in antiphospholipid syndrome

Area of Science:

• Immunology
• Cardiovascular Medicine
• Rheumatology

Background:

• Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by antiphospholipid antibodies (aPL).
• APS links inflammation and thrombosis, contributing to cardiovascular disease pathophysiology.
• It serves as a model for studying thromboinflammation and innate immunity's role in thrombosis.

Purpose of the Study:

• To review the mechanisms of thromboinflammation in APS.
• To identify cellular pathways and interactions involved in APS pathogenesis.
• To highlight potential therapeutic targets for APS and other thromboinflammatory diseases.

Main Methods:

• Review of scientific literature on APS, thromboinflammation, and innate immune cell activation.
• Analysis of cellular signaling pathways including NF-κB, mTOR, and inflammasomes.
• Examination of neutrophil extracellular trap (NET) formation and platelet activation in APS.

Main Results:

• aPL activate monocytes, promoting a pro-inflammatory and pro-coagulant state via cytokines and tissue factor.
• Neutrophils contribute to thrombosis through NETosis and enhanced interactions with endothelial cells.
• Platelet activation by aPL increases platelet-leukocyte interactions, contributing to a pro-coagulant phenotype.

Conclusions:

• Targeting pathways like NF-κB, mTOR, and inflammasomes offers therapeutic potential in APS.
• Interventions against NETosis and platelet activation present viable treatment strategies.
• Understanding APS thromboinflammation mechanisms can inform treatments for broader cardiovascular and autoimmune conditions.